Clinical progression free survival
Figure 1: · Panel A
Panel A 是同一 Figure 1: 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
A Dal Pra, P Ghadjar, H M Ryu, J A Proudfoot, S Hayoz, J M Michalski, D E Spratt, Y Liu, C Schär, A M Berlin, D R Zwahlen, J P Simko, T Hölscher, J A Efstathiou, B Polat, H M Sandler, G Hildebrandt, M B Parliament, A-C Mueller, I S Dayes, L Plasswilm, R J M Correa, J M Robertson, T G Karrison, E Davicioni, W A Hall, F Y Feng, A Pollack, G N Thalmann, P L Nguyen, D M Aebersold, P T Tran, S G Zhao
Ann Oncol 36(5) 572-582
BACKGROUND: The SAKK 09/10 trial randomized biochemically recurrent prostate cancer patients to salvage radiation 64 Gy versus 70 Gy, and the NRG/RTOG 0126 randomized intermediate-risk prostate cancer patients to definitive radiation 70.2 Gy versus 79.2 Gy. We investigated a previously developed Post-Operative Radiation Therapy Outcomes Score (PORTOS) to identify preferential benefit from radiation dose escalation (DE). MATERIALS AND METHODS: PORTOS was evaluated in patients enrolled in SAKK 09/10 and NRG/RTOG 0126 with available tissue that passed quality control (n = 226, 215). PORTOS was evaluated in the published post-operative groups in SAKK 09/10 and in tertiles in NRG/RTOG 0126 as cut-offs had not been established for biopsy samples and definitive radiation patients. Clinical and molecular correlates in a real-world dataset of 42 407 prostatectomy and 31 107 biopsy samples were also analyzed. RESULTS: In SAKK 09/10, the biomarker-treatment interaction was statistically significant between PORTOS (lower versus higher) and treatment arm for clinical progression-free survival. Only patients in the higher PORTOS group benefited from DE. In NRG/RTOG 0126, in patients with a lower tertile PORTOS, there was no difference in Phoenix biochemical failure (BF). However, for patients in the average and higher tertile PORTOS range, there was a significant benefit for DE for Phoenix BF. An interaction test indicated a significant difference in benefit for DE between higher and lower PORTOS groups. PORTOS was not strongly associated with clinicopathological variables in either trial or the large real-world dataset. In the latter, PORTOS was modestly associated with hypoxia signatures and strongly associated with immune signatures and subtypes. CONCLUSION: In the SAKK 09/10 and RTOG 0126 randomized controlled trials, we demonstrated that PORTOS can potentially identify a subset of patients who benefit from DE, a subgroup that cannot be identified using clinicopathological or prognostic variables. These results suggest that PORTOS could be used clinically as a predictor of radiation response.
1 个 Figure · 2 个 KM 面板
PORTOS Clinical Outcomes in SAKK 09/10. (A) Clinical progression free-survival (CPFS) Kaplan-Meier curves of patients with lower PORTOS scores in SAKK 09/10. (B) CPFS Kaplan-Meier curves of patients with higher PORTOS scores in SAKK 09/10. *p<0.05
Figure 1: · Panel A
Panel A 是同一 Figure 1: 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 1: · Panel B
Panel B 是同一 Figure 1: 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。